

NCCN Guidelines Updated to Include BRACAnalysis® Large Rearrangement Test (BART™)

NCCN Guideline Update on BART:

The BRACAnalysis Large Rearrangement Test (BART) was launched to provide a way to detect large genomic rearrangements in both *BRCA1* and *BRCA2* that are not identified as part of the BRACAnalysis sequencing test. Large rearrangement mutations account for 6-10% of all Hereditary Breast and Ovarian Cancer (HBOC) mutations identified.

The National Comprehensive Cancer Network (NCCN) has updated their HBOC guidelines to support the inclusion of large rearrangement testing (BART) for all patients undergoing genetic testing for the *BRCA1* and *BRCA2* genes.

How is BART ordered?

As described in the new NCCN recommendations, BART should be included for all patients undergoing BRACAnalysis. This test is ordered by checking the "Reflex to BART" box and will be run as a reflex on all patients who test negative for BRACAnalysis.

Myriad will continue to include BART testing at no additional charge as part of BRACAnalysis for patients who have an especially strong personal and family history of breast and ovarian cancer (see below for details of these criteria). Patients eligible for this free BART testing are identified based on the clinical history provided on the test requisition form by the ordering healthcare provider.

Criteria for inclusion of BART testing at no additional charge as part of BRACAnalysis:

Patient affected with:		Additional Family History Required:
Breast cancer before age 50	AND	2 or more diagnoses of breast cancer before age 50 ¹ and/or ovarian cancer at any age ²
OR		
Ovarian cancer at any age	AND	2 or more diagnoses of breast cancer before age 50 ¹ and/or ovarian cancer at any age ²
OR		
Male breast cancer at any age	AND	2 or more diagnoses of breast cancer before age 50 ¹ and/or ovarian cancer at any age ²
OR		
Breast cancer at or after age 50 and ovarian cancer at any age	AND	1 or more diagnosis of breast cancer before age 50 ¹ and/or ovarian cancer at any age ²
OR		
Breast cancer before age 50 and ovarian cancer at any age	AND	No additional relatives required

1. Male breast cancer qualifies at any age

2. At least one relative must be a first or second degree relative and qualifying cancers must be on the same side of the family

Note: For this criteria, "breast cancer" includes ductal carcinoma in situ (DCIS) and invasive breast cancers.

Will insurance cover the cost of BART?

Myriad will continue to work with insurers to determine coverage and update medical policy to reflect the new NCCN guidelines. For patients who meet the Myriad Financial Assistance Program criteria for BRACAnalysis, BART will be included as part of their testing. Additionally, any patient who receives a bill and has concerns can call the telephone number on the invoice. We guarantee that we will work together with the patient to reach a solution.

For more information and answers to frequently asked questions about BART go to www.myriadpro.com/BRAC_BART



Myriad Genetic Laboratories, Inc.
320 Wakara Way, Salt Lake City, Utah 84108
www.myriadpro.com

BRACAnalysis®